DNLI Stock Summary and Trading Ideas (Denali Therapeutics | NASDAQ:DNLI)

Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.

Denali Therapeutics trades on the NASDAQ stock market under the symbol DNLI.

As of February 20, 2026, DNLI stock price declined to $20.19 with 1,586,368 million shares trading.

DNLI has a beta of 1.78, meaning it tends to be more sensitive to market movements. DNLI has a correlation of 0.25 to the broad based SPY ETF.

DNLI has a market cap of $3.15 billion. This is considered a Mid Cap stock.

Last quarter Denali Therapeutics reported $0 in Revenue and -$.74 earnings per share. This fell short of revenue expectation by $-6 million and exceeded earnings estimates by $.02.

In the last 3 years, DNLI traded as high as $33.33 and as low as $10.57.

The top ETF exchange traded funds that DNLI belongs to (by Net Assets): VTI, XBI, VB, IWM, VBK.

DNLI has underperformed the market in the last year with a price return of -6.5% while the SPY ETF gained +14.1%. However, in the short term, DNLI had mixed performance relative to the market. It has outperformed in the last 3 months, returning +17.7% vs +6.0% return in SPY. But in the last 2 weeks, DNLI shares have been beat by the market, returning -4.2% compared to an SPY return of -0.2%.

DNLI support price is $19.30 and resistance is $21.18 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that DNLI shares will trade within this expected range on the day.